In a similar manner, stratifying lymphomas into inflamed or noninflamed based on the underlying patterns of tumor immunobiology is a rational approach since it provides the means of selecting patients that may benefit from a more personalized approach, incorporating ICIs in the treatment algorithm of disease entities that are sensitive to PD-1/PD-L1 therapy [22]. The gene discussed is CD274; the disease is lymphoma.